For the quarter ending 2025-09-30, ORKA had $25,857K increase in cash & cash equivalents over the period. -$21,701K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -30,277 | -45,573 |
| Stock-based compensation expense | 10,165 | 9,960 |
| Non-cash interest expense | - | 0 |
| Net accretion of premiums and discounts on marketable securities | 1,040 | 3,300 |
| Non-cash lease expense | 132 | 187 |
| Depreciation expense | 20 | 35 |
| Prepaid expenses and other current assets | 2,402 | 765 |
| Subscription receivable | - | 0 |
| Other non-current assets | 0 | 60 |
| Accrued interest payable, related party | - | 0 |
| Accounts payable | -2,456 | 1,202 |
| Accrued expenses and other current liabilities | 4,806 | 232 |
| Operating lease liability | -439 | -29 |
| Related party accounts payable and other current liabilities | -111 | -5,903 |
| Net cash used in operating activities | -21,602 | -44,014 |
| Purchases of property and equipment | 99 | 47 |
| Purchases of marketable securities | 267,683 | 152,289 |
| Proceeds from maturities of marketable securities | 145,333 | 200,062 |
| Net cash used in investing activities | -122,449 | 47,726 |
| Proceeds from issuance of notes payable to related party, net of issuance costs paid | - | 0 |
| Proceeds from issuance of pre-merger oruka series a preferred stock, net of issuance costs paid | - | 0 |
| Proceeds from the pipe financings, net | 169,908 | - |
| Proceeds from issuance of common stock | 0 | 109 |
| Payment of deferred offering costs | - | 0 |
| Net cash provided by financing activities | 169,908 | 109 |
| Net increase in cash and cash equivalents | 25,857 | 3,821 |
| Cash and cash equivalents at beginning of period | 61,575 | - |
| Cash and cash equivalents at end of period | 91,253 | - |
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)